[go: up one dir, main page]

AR069026A1 - Arilindenopirimidinas y su uso como antagonistas de los receptores de adenosina a₂a - Google Patents

Arilindenopirimidinas y su uso como antagonistas de los receptores de adenosina a₂a

Info

Publication number
AR069026A1
AR069026A1 ARP080104647A ARP080104647A AR069026A1 AR 069026 A1 AR069026 A1 AR 069026A1 AR P080104647 A ARP080104647 A AR P080104647A AR P080104647 A ARP080104647 A AR P080104647A AR 069026 A1 AR069026 A1 AR 069026A1
Authority
AR
Argentina
Prior art keywords
arylindenopirimidins
antagonists
adenosine receptors
arylindenopyrimidines
disorders
Prior art date
Application number
ARP080104647A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR069026A1 publication Critical patent/AR069026A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a arilindenopirimidinas, de fórmula (1), (2)y (3), y a sus usos terapéuticos y profilácticos. Los trastornos que se tratan o previenen utilizando estos compuestos incluyen la enfermedad de Parkinson.
ARP080104647A 2007-10-25 2008-10-24 Arilindenopirimidinas y su uso como antagonistas de los receptores de adenosina a₂a AR069026A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98245607P 2007-10-25 2007-10-25

Publications (1)

Publication Number Publication Date
AR069026A1 true AR069026A1 (es) 2009-12-23

Family

ID=40225283

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104647A AR069026A1 (es) 2007-10-25 2008-10-24 Arilindenopirimidinas y su uso como antagonistas de los receptores de adenosina a₂a

Country Status (13)

Country Link
US (1) US20090111804A1 (es)
EP (1) EP2220053B1 (es)
JP (1) JP2011500833A (es)
CN (1) CN101835760A (es)
AR (1) AR069026A1 (es)
AT (1) ATE509012T1 (es)
AU (1) AU2008316821A1 (es)
CL (1) CL2008003184A1 (es)
PA (1) PA8801401A1 (es)
PE (1) PE20091345A1 (es)
TW (1) TW200934496A (es)
UY (1) UY31421A1 (es)
WO (1) WO2009055548A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105540A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
CA3256033A1 (en) 2022-04-13 2023-10-19 Arcus Biosciences, Inc. POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH-2
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19627430A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
DE69803653T2 (de) * 1997-12-05 2002-08-29 F. Hoffmann-La Roche Ag, Basel 1,3,8-Triazaspiro[4,5]decan-4-on-derivate
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
ES2326075T3 (es) * 2003-10-03 2009-09-30 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Arilidenopiridinas y arilidenopirimidinas y su uso como antagonistas del receptor de adenosina a2a.

Also Published As

Publication number Publication date
EP2220053B1 (en) 2011-05-11
AU2008316821A1 (en) 2009-04-30
WO2009055548A1 (en) 2009-04-30
CN101835760A (zh) 2010-09-15
CL2008003184A1 (es) 2009-10-16
PA8801401A1 (es) 2009-05-15
US20090111804A1 (en) 2009-04-30
UY31421A1 (es) 2009-04-30
TW200934496A (en) 2009-08-16
PE20091345A1 (es) 2009-09-24
EP2220053A1 (en) 2010-08-25
JP2011500833A (ja) 2011-01-06
ATE509012T1 (de) 2011-05-15

Similar Documents

Publication Publication Date Title
NI201000005A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico.
CR10243A (es) "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos"
ECSP066856A (es) Compuestos novedosos como moduladores del receptor opioide
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
CR7168A (es) Ligandos del receptor de 5.ht y sus usos
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
NI200900100A (es) Antagonistas de receptor de orexina de diazepan sustituido
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
CL2011001263A1 (es) Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma.
UY32996A (es) Antagonistas del receptor crth2 basados en indol
CY1110882T1 (el) Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
CR7643A (es) Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
CR11303A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3
UY30534A1 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapéutica como antagonistas de los receptores de urotensina ii
DOP2006000014A (es) Derivados de triazol sustituidos como antagonistas de oxitocina
ECSP099573A (es) Derivados heterocíclicos como receptores muscarínicos m3
EA201170563A1 (ru) Метиленамины тиено[2,3-d]пиримидина и их применение в качестве антагонистов рецепторов a2a аденозина
AR069009A1 (es) Arilindenopirimidinas y su uso como antagonistas del receptor a₂a de adenosina
AR069026A1 (es) Arilindenopirimidinas y su uso como antagonistas de los receptores de adenosina a₂a
ECSP099679A (es) Nuevos compuestos y sus usos 707

Legal Events

Date Code Title Description
FB Suspension of granting procedure